Deep Vein Thrombosis: Diagnosis & Treatment Reginald E. Smith ...

More documents

Recommendations

Info

Does SYMPTOMATIC Calf DVT Require Treatment ? Calf DVT, treated initially with intravenous UFH then long term therapy OAC vs no treatment Recurrence during first 3 months Recurrence during first year OAC No Rx 0 / 23 (0%) 1 / 23 8 / 28 (28.5%) 9 / 28 Recurrence 3 Months: Treatment vs No Treatment ARR=28.5% NNT= 3.5 Lagerstedt Lancet 1985:2;515 36
Treatment of DVT/PE Recommendations from 8th ACCP Guidelines First-episode secondary to transient risk factor Warfarin for 3 months First-episode idiopathic Warfarin for at least 3 months; Long-term therapy based upon risk-benefit ratio Antiphospholipid antibodies or ≥2 thrombophilic conditions Treat for 12 months; consider indefinite anticoagulant therapy First episode with deficiency of antithrombin III, protein C or S, factor V Leiden or prothrombin 20210 gene mutation, hyperhomocysteinemia, or high factor VIII levels Treat for 6 to 12 months; indefinite therapy for patients with idiopathic thrombosis ≥2 episodes Indefinite treatment Kearon C, et al. Chest 2008;133;454S-545S 37
Page 1 and 2: Deep Vein Thrombosis: Diagnosis & T
Page 3 and 4: Fail or Win 3
Page 6 and 7: Virchow’s Triad and Thrombus Form
Page 8 and 9: Pathophysiology of DVT Most Often
Page 11 and 12: Late Presentation Is Common The Ris
Page 13 and 14: WELLS Scale For Pretest Probability
Page 15 and 16: Sensitivity & Specificity Of D-Dime
Page 17 and 18: Compression Ultrasound Lower Extrem
Page 19 and 20: Deep Vein Clots Are Big Measured In
Page 21 and 22: Pulmonary Embolism 21
Page 23 and 24: Pulmonary Embolism: A Life-threaten
Page 25 and 26: Diagnostic Testing for PE CT Angiog
Page 27 and 28: Acute Pulmonary Embolism R Axis Dev
Page 29: Grade IA Symptomatic Proximal DVT G
Page 32 and 33: Therapy: Do We Need To Anticoagulat
Page 34 and 35: Overlapping Heparins, LMWH or Fonda
Page 38 and 39: Cancer Associated Thrombosis 38
Page 40 and 41: Treatment Of Cancer Associated Thro
Page 42 and 43: Novel Anticoagulants: The Future of
Page 44 and 45: New Oral Anticoagulant Agents In De
Page 46 and 47: Dabigatran etexilate: a novel direc
Page 48 and 49: RE-LY ® - study design Atrial fibr
Page 50 and 51: Major bleeding rates 3.50 3.00 2.50
Page 52 and 53: Most common adverse events Dabigatr
Page 54 and 55: RE-COVER TM Trial Design Singledumm
Page 56 and 57: Cumulative risk of first event of m
Page 58 and 59: Dabigatran: How To Measure Effect?
Page 60: Bleeding Management Withhold Dabiga
Page 63 and 64: Rivaroxaban Brand name Xarelto ® ,
Page 65 and 66: Effect of Rivaroxaban On Coagulatio

Deep Vein Thrombosis: Diagnosis & Treatment Reginald E. Smith ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?